Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter March 2, 2013

Post-translational modification derived products (PTMDPs): toxins in chronic diseases?

  • Philippe Gillery EMAIL logo and Stéphane Jaisson

Abstract

In living organisms, proteins are progressively modified by spontaneous non-enzymatic reactions generating many post-translational modification derived products (PTMDPs) which exert deleterious effects and may be considered endogenous toxins in diabetes mellitus and chronic renal failure. Non-enzymatic glycation, which refers to the spontaneous binding of reducing sugars to free amino groups, is increased in diabetes mellitus because of hyperglycemia and is amplified by oxidative processes (‘glycoxidation’). Glycoxidation leads to the formation of ‘advanced glycation end products’ (AGEs), together with products of other oxidative pathways. AGEs alter tissue organization and cell-protein interactions, mainly in the case of long-lived extracellular matrix proteins, and interact with membrane receptors, among which RAGE (receptor of AGEs), a multiligand receptor which triggers intracellular signaling pathways stimulating inflammatory functions. Another major protein modification, carbamylation, is increased in chronic renal failure, which may occur during the course of diabetes mellitus. Carbamylation is due to the binding of isocyanic acid on the α-NH2 extremity of proteins or amino acids, or on ε-NH2 lysine groups, generating homocitrulline, a potential biomarker in atherosclerosis. Isocyanic acid is formed in vivo either by spontaneous dissociation of urea or by myeloperoxidase action on thiocyanate. Carbamylated proteins exhibit altered properties. For example, carbamylated collagen is unable to stimulate oxidative functions of polymorphonuclear neutrophils but increases matrix metalloproteinase-9 production by monocytes. Lipoprotein functions are altered by carbamylation and may contribute to atherogenesis. Thus, the numerous PTMDPs may be considered both hallmarks of protein damage in chronic diseases and endogenous toxins acting at the molecular and cellular levels.


Corresponding author: Professor Philippe Gillery, MD, PhD, Laboratory of Pediatric Biology and Research, American Memorial Hospital, CHU of Reims, 47, Rue Cognacq-Jay, 51092 Reims cedex, France, Phone: +33 3 26783952, Fax: +33 3 26783882, E-mail:

References

1. Jaisson S, Gillery P. Evaluation of nonenzymatic posttranslational modification-derived products as biomarkers of molecular aging of proteins. Clin Chem 2010;56:1401–12.10.1373/clinchem.2010.145201Search in Google Scholar

2. Jaisson S, Pietrement C, Gillery P. Carbamylation derived products (CDPs): bioactive compounds and potential biomarkers in chronic renal failure and atherosclerosis. Clin Chem 2011;57:1499–505.10.1373/clinchem.2011.163188Search in Google Scholar

3. D’Agati V, Schmidt AM. RAGE and the pathogenesis of chronic kidney disease. Nature Rev Nephrol 2010;6:352–60.10.1038/nrneph.2010.54Search in Google Scholar

4. Ahmed N, Thornalley PJ. Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes Obes Metab 2007;9:233–45.10.1111/j.1463-1326.2006.00595.xSearch in Google Scholar

5. Gillery P. A history of HbA1c through Clinical Chemistry and Laboratory Medicine. Clin Chem Lab Med 2013;51:65–74.10.1515/cclm-2012-0548Search in Google Scholar

6. Mosca A, Lapolla A, Gillery P. Glycemic control in the clinical management of diabetic patients. Clin Chem Lab Med 2013;51:753–66.10.1515/cclm-2012-0594Search in Google Scholar

7. Baynes JW, Thorpe SR. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 2000;28;1708–16.10.1016/S0891-5849(00)00228-8Search in Google Scholar

8. Baynes JW. Chemical modification of proteins by lipids in diabetes. Clin Chem Lab Med 2003;41:1159–65.10.1515/CCLM.2003.179Search in Google Scholar PubMed

9. Witko-Sarsat V, Nguyen-Khoa T, Jungers P, Drueke TB, Descamps-Latscha B. Advanced oxidation protein products as a novel molecular basis of oxidative stress in uraemia. Nephrol Dial Transplant 1999;14(Suppl 1):76–8.10.1093/ndt/14.suppl_1.76Search in Google Scholar PubMed

10. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006;114:597–605.10.1161/CIRCULATIONAHA.106.621854Search in Google Scholar PubMed

11. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 2008;196:9–21.10.1016/j.atherosclerosis.2007.07.025Search in Google Scholar

12. Takeuchi M, Yamagishi S. Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer’s disease. J Alzheimers Dis 2009;16:845–58.10.3233/JAD-2009-0974Search in Google Scholar

13. Vlassara H, Striker G. Glycotoxins in the diet promote diabetes and diabetic complications. Curr Diab Rep 2007;7:235–41.10.1007/s11892-007-0037-zSearch in Google Scholar

14. Gillery P, Monboisse JC, Maquart FX, Borel JP. Glycation of proteins as a source of superoxide. Diab Metab 1988;14: 25–30.Search in Google Scholar

15. Bailey AJ, Paul RG, Knott L. Mechanisms of maturation and ageing of collagen. Mech Ageing Dev 1998;106:1–56.10.1016/S0047-6374(98)00119-5Search in Google Scholar

16. Monboisse JC, Rittié L, Lamfarraj H, Garnotel R, Gillery P. In vitro glycoxidation alters the interactions between collagens and human polymorphonuclear leucocytes. Biochem J 2000;350:777–83.10.1042/bj3500777Search in Google Scholar

17. Touré F, Zahm JM, Garnotel R, Lambert E, Bonnet N, Schmidt AM, et al. Receptor for advanced glycation end products (RAGE) modulates neutrophil adhesion and migration on glycoxidated extracellular matrix. Biochem J 2008;416:255–61.10.1042/BJ20080054Search in Google Scholar

18. Thornalley PJ. Advanced glycation end products in renal failure. J Ren Nutr 2006;16:178–84.10.1053/j.jrn.2006.04.012Search in Google Scholar

19. Stark GR, Stein WH, Moore S. Reactions of the cyanate present in aqueous urea with aminoacids and proteins. J Biol Chem 1960;235:3177–81.10.1016/S0021-9258(20)81332-5Search in Google Scholar

20. Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Hörkkö S, Barnard J, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007;13:1167–84.10.1038/nm1637Search in Google Scholar PubMed

21. Roberts JM, Veres PR, Cochran AK, Warneke C, Burling IR, Yokelson RJ, et al. Isocyanic acid in the atmosphere and its possible link to smoke related health effects. Proc Natl Acad Sci USA 2011;108:8966–71.10.1073/pnas.1103352108Search in Google Scholar PubMed PubMed Central

22. Kraus LM, Kraus AP Jr. Carbamoylation of amino acids and proteins in uremia. Kidney Int Suppl 2001;78:S102–7.10.1046/j.1523-1755.2001.07811.xSearch in Google Scholar

23. Kraus LM, Jones MR, Kraus AP Jr. Essential carbamoyl-amino acids formed in vivo in patients with end-stage renal disease managed by continuous ambulatory peritoneal dialysis: isolation, identification, and quantitation. J Lab Clin Med 1998;131:425–31.10.1016/S0022-2143(98)90143-3Search in Google Scholar

24. Kraus LM, Kraus AP Jr. The search for the uremic toxin: the case for carbamoylation of amino acids and proteins. Wien Klin Wochenschr 1998;110:521–30.Search in Google Scholar

25. Schreier SM, Hollaus M, Hermann M, Jirovetz L, Exner M, Kapiotis S, et al. Carbamoylated free amino acids in uremia: HOCl generates volatile protein modifying and cytotoxic oxidant species form N-carbamoyl-threonine but not threonine. Biochimie 2012;94:2441–7.10.1016/j.biochi.2012.06.032Search in Google Scholar PubMed

26. Dengler TJ, Robertz-Vaupel GM, Dengler HJ. Albumin binding in uremia: quantitative assessment of inhibition by endogenous ligands and carbamylation of albumin. Eur J Clin Pharmacol 1992;43:491–9.10.1007/BF02285090Search in Google Scholar PubMed

27. Jaisson S, Delevallée-Forte C, Touré F, Rieu P, Garnotel R, Gillery P. Carbamylated albumin is a potent inhibitor of polymorphonuclear neutrophil respiratory burst. FEBS Lett 2007;581:1509–13.10.1016/j.febslet.2007.03.008Search in Google Scholar PubMed

28. Gross ML, Piecha G, Bierhaus A, Hanke W, Henle, T, Schirmacher P, et al. Glycated and carbamylated albumin are more “nephrotoxic” than unmodified albumin in the amphibian kidney. Am J Physiol Renal Physiol 2011;301:F476–85.10.1152/ajprenal.00342.2010Search in Google Scholar PubMed

29. Apostolov EO, Shah SV, Ok E, Basnakian AG. Carbamylated low-density lipoprotein induces monocyte adhesion to endothelial cells through intercellular adhesion molecule-1 and vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol 2007;27:826–32.10.1161/01.ATV.0000258795.75121.8aSearch in Google Scholar PubMed

30. Asci G, Basci A, Shah SV, Basnakian A, Toz H, Ozkahya M, et al. Carbamylated low-density lipoprotein induces proliferation and increases adhesion molecule expression of human coronary artery smooth muscle cells. Nephrology 2008;13:480–6.10.1111/j.1440-1797.2008.00948.xSearch in Google Scholar PubMed

31. Carracedo J, Merino A, Briceno C, Soriano S, Buendia P, Calleros L, et al. Carbamylated low-density lipoprotein induces oxidative stress and accelerated senescence in human endothelial progenitor cells. FASEB J 2011;25:1314–22.10.1096/fj.10-173377Search in Google Scholar PubMed

32. Holzer M, Birner-Gruenberger R, Stojakovic T, El-Gamal D, Binder V, Wadsack C, et al. Uremia alters HDL composition and function. J Am Soc Nephrol 2011;22:1631–41.10.1681/ASN.2010111144Search in Google Scholar PubMed PubMed Central

33. Holzer M, Zangger K, El-Gamal D, Binder V, Curcic S, Konya V, et al. Myeloperoxidase-derived chlorinating species induce protein carbamylation through decomposition of thiocyanate and urea: novel pathways generating dysfunctional high-density lipoprotein. Antioxid Redox Signal 2012;8:1043–52.10.1089/ars.2011.4403Search in Google Scholar

34. Nigen AM, Njikam N, Lee CK, Manning JM. Studies on the mechanism of action of cyanate in sickle cell disease. Oxygen affinity and gelling properties of hemoglobin S carbamylated on specific chains. J Biol Chem 1974;249:6611–6.10.1016/S0021-9258(19)42200-XSearch in Google Scholar

35. Harding JJ. Viewing molecular mechanisms of ageing through a lens. Ageing Res Rev 2002;1:465–79.10.1016/S1568-1637(02)00012-0Search in Google Scholar

36. Jaisson S, Lorimier S, Ricard-Blum S, Sockalingum GD, Delevallée-Forte C, Kegelaer G, et al. Impact of carbamylation on type I collagen conformational structure and its ability to activate human polymorphonuclear neutrophils. Chem Biol 2006;13:149–59.10.1016/j.chembiol.2005.11.005Search in Google Scholar

37. Jaisson S, Larreta-Garde V, Bellon G, Hornebeck W, Garnotel R, Gillery P. Carbamylation differentially alters type I collagen sensitivity to various collagenases. Matrix Biol 2007;26: 190–6.10.1016/j.matbio.2006.10.008Search in Google Scholar

38. Garnotel R, Sabbah N, Jaisson S, Gillery P. Enhanced activation of and increased production of matrix metalloproteinase-9 by human blood monocytes upon adhering to carbamylated collagen. FEBS Lett 2004;563:13–610.1016/S0014-5793(04)00233-9Search in Google Scholar

39. Shaykh M, Pegoraro AA, Mo W, Arruda JA, Dunea G, Singh AK. Carbamylated proteins activate glomerular mesangial cells and stimulate collagen deposition. J Lab Clin Med 1999;133:302–8.10.1016/S0022-2143(99)90086-0Search in Google Scholar

40. Kraus LM, Gaber L, Handorf CR, Marti HP, Kraus AP Jr. Carbamoylation of glomerular and tubular proteins in patients with kidney failure: a potential mechanism of ongoing renal damage. Swiss Med Wkly 2001;131:139–45.10.4414/smw.2001.09691Search in Google Scholar

Received: 2012-12-14
Accepted: 2013-2-4
Published Online: 2013-03-02
Published in Print: 2014-01-01

©2014 by Walter de Gruyter Berlin Boston

Downloaded on 28.3.2024 from https://www.degruyter.com/document/doi/10.1515/cclm-2012-0880/html
Scroll to top button